Phase II Trial of Treatment Intensification for IDH Wildtype, Non-Histological Glioblastoma, Gliomas (IDH Wildtype Lower Grade Glioma Treatment Intensification)
Latest Information Update: 24 Apr 2023
At a glance
- Drugs Temozolomide (Primary)
- Indications Astrocytoma; Glioblastoma; Oligodendroglioma
- Focus Therapeutic Use
- 18 Apr 2023 Planned End Date changed from 6 Dec 2026 to 31 Dec 2026.
- 18 Apr 2023 Planned primary completion date changed from 1 Dec 2026 to 31 Dec 2026.
- 08 Dec 2022 Planned End Date changed from 6 Sep 2023 to 6 Dec 2026.